nodes	percent_of_prediction	percent_of_DWPC	metapath
Etravirine—CYP2C19—Thalidomide—leprosy	0.136	0.149	CbGbCtD
Etravirine—CYP2C19—Rifampicin—leprosy	0.131	0.144	CbGbCtD
Etravirine—CYP2C9—Thalidomide—leprosy	0.113	0.124	CbGbCtD
Etravirine—CYP2C9—Rifampicin—leprosy	0.109	0.12	CbGbCtD
Etravirine—CYP2C19—Dapsone—leprosy	0.108	0.119	CbGbCtD
Etravirine—ABCB1—Rifampicin—leprosy	0.106	0.117	CbGbCtD
Etravirine—CYP2C9—Dapsone—leprosy	0.0901	0.0991	CbGbCtD
Etravirine—CYP3A4—Rifampicin—leprosy	0.0635	0.0698	CbGbCtD
Etravirine—CYP3A4—Dapsone—leprosy	0.0524	0.0576	CbGbCtD
Etravirine—Swelling face—Dapsone—leprosy	0.00676	0.0743	CcSEcCtD
Etravirine—Autoimmune disorder—Thalidomide—leprosy	0.00493	0.0543	CcSEcCtD
Etravirine—Hepatomegaly—Thalidomide—leprosy	0.00233	0.0256	CcSEcCtD
Etravirine—Hyperlipidaemia—Thalidomide—leprosy	0.00228	0.0251	CcSEcCtD
Etravirine—Pancreatitis—Dapsone—leprosy	0.00198	0.0218	CcSEcCtD
Etravirine—Blood disorder—Thalidomide—leprosy	0.00197	0.0217	CcSEcCtD
Etravirine—Neuropathy peripheral—Dapsone—leprosy	0.00176	0.0194	CcSEcCtD
Etravirine—Hypercholesterolaemia—Thalidomide—leprosy	0.00174	0.0192	CcSEcCtD
Etravirine—Gynaecomastia—Thalidomide—leprosy	0.00147	0.0162	CcSEcCtD
Etravirine—Diabetes mellitus—Thalidomide—leprosy	0.00137	0.0151	CcSEcCtD
Etravirine—Vision blurred—Dapsone—leprosy	0.00133	0.0146	CcSEcCtD
Etravirine—Renal failure acute—Thalidomide—leprosy	0.00129	0.0142	CcSEcCtD
Etravirine—Amnesia—Thalidomide—leprosy	0.00127	0.014	CcSEcCtD
Etravirine—Vertigo—Dapsone—leprosy	0.00126	0.0139	CcSEcCtD
Etravirine—Atrial fibrillation—Thalidomide—leprosy	0.00126	0.0139	CcSEcCtD
Etravirine—Dermatitis bullous—Thalidomide—leprosy	0.00125	0.0138	CcSEcCtD
Etravirine—Dry skin—Thalidomide—leprosy	0.0011	0.0121	CcSEcCtD
Etravirine—Breast disorder—Thalidomide—leprosy	0.00108	0.0119	CcSEcCtD
Etravirine—Toxic epidermal necrolysis—Thalidomide—leprosy	0.00108	0.0118	CcSEcCtD
Etravirine—Abdominal distension—Thalidomide—leprosy	0.00104	0.0114	CcSEcCtD
Etravirine—Insomnia—Dapsone—leprosy	0.00104	0.0114	CcSEcCtD
Etravirine—Eosinophilia—Thalidomide—leprosy	0.00102	0.0113	CcSEcCtD
Etravirine—Bronchospasm—Thalidomide—leprosy	0.00102	0.0112	CcSEcCtD
Etravirine—Pancreatitis—Thalidomide—leprosy	0.00101	0.0111	CcSEcCtD
Etravirine—Angina pectoris—Thalidomide—leprosy	0.00101	0.0111	CcSEcCtD
Etravirine—Gastrointestinal pain—Dapsone—leprosy	0.000938	0.0103	CcSEcCtD
Etravirine—Hyperglycaemia—Thalidomide—leprosy	0.000932	0.0103	CcSEcCtD
Etravirine—Stevens-Johnson syndrome—Thalidomide—leprosy	0.000913	0.01	CcSEcCtD
Etravirine—Acute coronary syndrome—Thalidomide—leprosy	0.000908	0.00999	CcSEcCtD
Etravirine—Body temperature increased—Dapsone—leprosy	0.000907	0.00998	CcSEcCtD
Etravirine—Abdominal pain—Dapsone—leprosy	0.000907	0.00998	CcSEcCtD
Etravirine—Renal failure—Thalidomide—leprosy	0.000905	0.00996	CcSEcCtD
Etravirine—Neuropathy peripheral—Thalidomide—leprosy	0.000903	0.00994	CcSEcCtD
Etravirine—Myocardial infarction—Thalidomide—leprosy	0.000903	0.00994	CcSEcCtD
Etravirine—Stomatitis—Thalidomide—leprosy	0.000898	0.00988	CcSEcCtD
Etravirine—Conjunctivitis—Thalidomide—leprosy	0.000895	0.00985	CcSEcCtD
Etravirine—Hepatitis—Thalidomide—leprosy	0.000827	0.0091	CcSEcCtD
Etravirine—Hypoaesthesia—Thalidomide—leprosy	0.000823	0.00905	CcSEcCtD
Etravirine—Urinary tract disorder—Thalidomide—leprosy	0.000817	0.00899	CcSEcCtD
Etravirine—Urethral disorder—Thalidomide—leprosy	0.000811	0.00892	CcSEcCtD
Etravirine—Erythema multiforme—Thalidomide—leprosy	0.000782	0.0086	CcSEcCtD
Etravirine—Eye disorder—Thalidomide—leprosy	0.000773	0.0085	CcSEcCtD
Etravirine—Cardiac disorder—Thalidomide—leprosy	0.000767	0.00845	CcSEcCtD
Etravirine—Angiopathy—Thalidomide—leprosy	0.00075	0.00826	CcSEcCtD
Etravirine—Immune system disorder—Thalidomide—leprosy	0.000747	0.00822	CcSEcCtD
Etravirine—Mediastinal disorder—Thalidomide—leprosy	0.000745	0.0082	CcSEcCtD
Etravirine—Vomiting—Dapsone—leprosy	0.00073	0.00803	CcSEcCtD
Etravirine—Mental disorder—Thalidomide—leprosy	0.000724	0.00797	CcSEcCtD
Etravirine—Malnutrition—Thalidomide—leprosy	0.00072	0.00792	CcSEcCtD
Etravirine—Headache—Dapsone—leprosy	0.000719	0.00791	CcSEcCtD
Etravirine—Flatulence—Thalidomide—leprosy	0.000709	0.00781	CcSEcCtD
Etravirine—Tension—Thalidomide—leprosy	0.000706	0.00777	CcSEcCtD
Etravirine—Nervousness—Thalidomide—leprosy	0.000699	0.00769	CcSEcCtD
Etravirine—Nausea—Dapsone—leprosy	0.000682	0.0075	CcSEcCtD
Etravirine—Vision blurred—Thalidomide—leprosy	0.000678	0.00747	CcSEcCtD
Etravirine—Tremor—Thalidomide—leprosy	0.000674	0.00742	CcSEcCtD
Etravirine—Ill-defined disorder—Thalidomide—leprosy	0.000668	0.00735	CcSEcCtD
Etravirine—Anaemia—Thalidomide—leprosy	0.000665	0.00732	CcSEcCtD
Etravirine—Angioedema—Thalidomide—leprosy	0.000658	0.00724	CcSEcCtD
Etravirine—Malaise—Thalidomide—leprosy	0.000649	0.00714	CcSEcCtD
Etravirine—Vertigo—Thalidomide—leprosy	0.000647	0.00712	CcSEcCtD
Etravirine—Syncope—Thalidomide—leprosy	0.000645	0.0071	CcSEcCtD
Etravirine—Loss of consciousness—Thalidomide—leprosy	0.000633	0.00696	CcSEcCtD
Etravirine—Convulsion—Thalidomide—leprosy	0.000624	0.00686	CcSEcCtD
Etravirine—Hypertension—Thalidomide—leprosy	0.000621	0.00684	CcSEcCtD
Etravirine—Anxiety—Thalidomide—leprosy	0.000611	0.00672	CcSEcCtD
Etravirine—Unspecified disorder of skin and subcutaneous tissue—Thalidomide—leprosy	0.000609	0.0067	CcSEcCtD
Etravirine—Discomfort—Thalidomide—leprosy	0.000605	0.00666	CcSEcCtD
Etravirine—Dry mouth—Thalidomide—leprosy	0.000599	0.0066	CcSEcCtD
Etravirine—Confusional state—Thalidomide—leprosy	0.000592	0.00652	CcSEcCtD
Etravirine—Infection—Thalidomide—leprosy	0.000584	0.00642	CcSEcCtD
Etravirine—Shock—Thalidomide—leprosy	0.000578	0.00636	CcSEcCtD
Etravirine—Nervous system disorder—Thalidomide—leprosy	0.000576	0.00634	CcSEcCtD
Etravirine—Thrombocytopenia—Thalidomide—leprosy	0.000575	0.00633	CcSEcCtD
Etravirine—Skin disorder—Thalidomide—leprosy	0.000571	0.00628	CcSEcCtD
Etravirine—Hyperhidrosis—Thalidomide—leprosy	0.000568	0.00625	CcSEcCtD
Etravirine—Anorexia—Thalidomide—leprosy	0.00056	0.00616	CcSEcCtD
Etravirine—Insomnia—Thalidomide—leprosy	0.000531	0.00585	CcSEcCtD
Etravirine—Paraesthesia—Thalidomide—leprosy	0.000527	0.00581	CcSEcCtD
Etravirine—Somnolence—Thalidomide—leprosy	0.000522	0.00575	CcSEcCtD
Etravirine—Decreased appetite—Thalidomide—leprosy	0.000511	0.00562	CcSEcCtD
Etravirine—Gastrointestinal disorder—Thalidomide—leprosy	0.000507	0.00558	CcSEcCtD
Etravirine—Fatigue—Thalidomide—leprosy	0.000506	0.00557	CcSEcCtD
Etravirine—Constipation—Thalidomide—leprosy	0.000502	0.00553	CcSEcCtD
Etravirine—Pain—Thalidomide—leprosy	0.000502	0.00553	CcSEcCtD
Etravirine—Feeling abnormal—Thalidomide—leprosy	0.000484	0.00533	CcSEcCtD
Etravirine—Gastrointestinal pain—Thalidomide—leprosy	0.00048	0.00529	CcSEcCtD
Etravirine—Abdominal pain—Thalidomide—leprosy	0.000464	0.00511	CcSEcCtD
Etravirine—Body temperature increased—Thalidomide—leprosy	0.000464	0.00511	CcSEcCtD
Etravirine—Hypersensitivity—Thalidomide—leprosy	0.000433	0.00476	CcSEcCtD
Etravirine—Asthenia—Thalidomide—leprosy	0.000421	0.00464	CcSEcCtD
Etravirine—Diarrhoea—Thalidomide—leprosy	0.000402	0.00442	CcSEcCtD
Etravirine—Dizziness—Thalidomide—leprosy	0.000388	0.00428	CcSEcCtD
Etravirine—Vomiting—Thalidomide—leprosy	0.000373	0.00411	CcSEcCtD
Etravirine—Rash—Thalidomide—leprosy	0.00037	0.00408	CcSEcCtD
Etravirine—Dermatitis—Thalidomide—leprosy	0.00037	0.00407	CcSEcCtD
Etravirine—Headache—Thalidomide—leprosy	0.000368	0.00405	CcSEcCtD
Etravirine—Nausea—Thalidomide—leprosy	0.000349	0.00384	CcSEcCtD
